- Search CSN:
- Members: Login to search all areas
- Not a member? Click here to search public areas
You are here
Coronavirus/COVID-19
What cancer patients, their families, and caregivers need to know about COVID-19.
Research item on how variations in KRAS-wild status impact Cetuximab effectiveness
|
|
Apr 01, 2013 - 4:04 pm
www.biomedcentral.com/1471-2407/13/169/abstract (there's more info in the link attached but this is all rather "technical") |
Joined: Apr 2004
Interesting
Increasing thespecificity of chemo would be great. Preventing people who won't benefit from a drug having to be exposed to it will reduce the harm associated with them.
Steve
Joined: Oct 2009
From one steve to another: there's a little more of such info
here
www.onclive.com/publications/obtn/2013/march-2013/molecular-pathways-pathways-and-more-pathways/1
Tho EGFR and KRAS get the most attention. (Hope with each passing day you feel better)
Joined: Apr 2004
Is practice keeping up?
Meeting with oncologist next week and will ask if testing anything more than kras in practice yet.
Slowly recovery moving forward here, thanks for your continued academic stimulation,
Steve
Joined: Oct 2009
perhaps you'll find this interesting
http://cancerres.aacrjournals.org/content/73/7/2059
Seems like every research team has their "pet" biomarker or factor that may predict future,so to speak. All here are aware of CEA but there may be other indicators as well that may be more pertinent